| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EVI5L |
| Uniprot No | Q96CN4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-794aa |
| 氨基酸序列 | MASPTLSPDSSSQEALSAPTCSPTSDSENLSPDELELLAKLEEQNRLLEADSKSMRSMNGSRRNSGSSLVSSSSASSNLSHLEEDTWILWGRIANEWEEWRRRKEKLLKELIRKGIPHHFRAIVWQLLCSATDMPVKNQYSELLKMSSPCEKLIRRDIARTYPEHEFFKGQDSLGQEVLFNVMKAYSLVDREVGYCQGSAFIVGLLLMQMPEEEAFCVFVRLMQEYRLRELFKPSMAELGLCIYQFEYMLQEQLPDLNTHFRSQSFHTSMYASSWFLTLFLTTFPLPVATRVFDIFMYEGLEIVFRVGLALLQVNQAELMQLDMEGMSQYFQRVIPHQFDSCPDKLVLKAYQVKYNPKKMKRLEKEYAAMKSKEMEEQIEIKRLRTENRLLKQRIETLEKGQVTRAQEAEENYVIKRELAVVRQQCSSAAEDLQKAQSTIRQLQEQQENPRLTEDFVSHLETELEQSRLRETETLGALREMQDKVLDMEKRNSSLPDENNVAQLQEELKALKVREGQAVASTRELKLQLQELSDTWQAHLARGGRWKESPRKLVVGELQDELMSVRLREAQALAEGRELRQRVVELETQDHIHRNLLNRVEAERAALQEKLQYLAAQNKGLQTQLSESRRKQAEAECKSKEEVMAVRLREADSMAAVAEMRQRIAELEIQREEGRIQGQLNHSDSSQYIRELKDQIEELKAEVRLLKGPPPFEDPLAFDGLSLARHLDEDSLPSSDEELLGVGVGAALQDALYPLSPRDARFFRRLERPAKDSEGSSDSDADELAAPYSQGLDN |
| 分子量 | 117.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EVI5L蛋白研究的假设性文献示例(注意：以下为虚构内容，实际文献需通过学术数据库检索)：
1. **文献名称**: *"Expression and Functional Analysis of Recombinant Human EVI5L in Cell Cycle Regulation"*
**作者**: Chen, L. et al. (2018)
**摘要**: 本研究通过大肠杆菌表达系统成功制备了重组人EVI5L蛋白，证实其通过结合APC/C复合体调控G2/M期转换，并在癌细胞中表现出促增殖活性。
2. **文献名称**: *"Recombinant EVI5L Protein Attenuates Neuronal Apoptosis in Parkinson’s Disease Models"*
**作者**: Zhang, Y. et al. (2020)
**摘要**: 首次利用哺乳动物细胞表达的重组EVI5L蛋白进行功能研究，发现其通过抑制线粒体凋亡通路，在帕金森病小鼠模型中减轻多巴胺能神经元损伤。
3. **文献名称**: *"Structural Characterization of EVI5L and Its Role in Hepatitis B Virus Replication"*
**作者**: Wang, H. et al. (2019)
**摘要**: 报道了重组人EVI5L的晶体结构，揭示其与病毒蛋白HBx相互作用的结构基础，并证明其过表达可抑制乙肝病毒的复制。
4. **文献名称**: *"High-Yield Purification of Recombinant EVI5L for Drug Screening Applications"*
**作者**: Li, X. et al. (2021)
**摘要**: 开发了一种高效纯化重组EVI5L蛋白的层析技术，优化后的蛋白可用于高通量筛选靶向EVI5L的抗癌先导化合物。
**提示**：实际引用时请通过PubMed、Web of Science或Google Scholar检索真实文献(关键词：recombinant EVI5L、human EVI5L protein)。
EVI5L (Ecotropic Viral Integration Site 5-Like), also known as TBC1D26. is a human protein involved in cellular processes such as vesicle trafficking, cell cycle regulation, and membrane dynamics. It belongs to the Tre-2/Bub2/Cdc16 (TBC) domain-containing protein family, functioning as a GTPase-activating protein (GAP) for Rab GTPases, which regulate intracellular transport and signaling pathways. The EVI5L gene is evolutionarily conserved and shares structural homology with EVI5. a protein implicated in leukemia through retroviral integration events.
Recombinant human EVI5L protein is artificially expressed in vitro using systems like E. coli or mammalian cells, enabling functional and structural studies. Its production facilitates research into its role in cytokinesis, neuronal development, and diseases. Notably, EVI5L dysregulation has been linked to neurodegenerative disorders (e.g., Alzheimer’s disease) and cancers, as it interacts with proteins involved in mitotic progression and autophagy. Recent studies highlight its potential as a biomarker or therapeutic target, particularly in glioma and leukemia. Recombinant EVI5L is instrumental in deciphering molecular mechanisms, protein-protein interactions, and screening for modulators of its GAP activity. Ongoing research continues to explore its dual roles in physiological homeostasis and pathological conditions.
×
